

INFORMATION DISCLOSURE
STATEMENT

BY APPLICANT

Docket: 4239-60808

App: _____

Applicant: Shearer et al.

Filed: Herewith

Art Unit: _____

U.S. PATENT DOCUMENTS

Init.*	Number	Date	Name	Class	Sub	Filed
MB	4,728,614	3/1/1988	Lau	_____	_____	
	5,095,095	3/10/1992	Fontana	_____	_____	
	5,468,481	11/21/1995	Sharma et al.	_____	_____	
MB	5,871,728	2/16/1999	Thomson et al.	_____	_____	

FOREIGN PATENT DOCUMENTS

	Number	Date	Country	Class	Sub	
MB	0 155 433	25.09.85	EPC	_____	_____	
	0 159 289	23.10.85	EPC	_____	_____	
MB	WO 96/29394	26.09.96	PCT	_____	_____	

OTHER DOCUMENTS

MB		ATCC No.: CRL-1690, 2003
		ATCC No.: CRL-2020, 2003
MB		ATCC No.: CRL-2365, 2003


EXAMINER: 

DATE

10/23/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Docket: 4239-60808	App: _____
			Applicant: Shearer et al.	
			Filed: Herewith	Art Unit: _____
OTHER DOCUMENTS				
MB			ATCC No.: CRL-2366, 2003	
			ATCC No.: HTB-16, 2003	
			ATCC No.: CRL-1620, 2003	
			"TGF-beta 2 Antisense Gene Therapy for Glioblastoma," <i>Cytokine Bulletin</i> , Spring 1997.	
			Bluestone, "Transplantation Tolerance: The Next Frontier," <i>New Developments in Transplantation Medicine</i> , Vol. 1, Spring 1994.	
			Elliott et al., "Suppression of High Affinity IL-2 Receptors on Mitogen Activated Lymphocytes by Glioma-Derived Suppressor Factor," <i>J. Neuro-Oncol.</i> 14:1-7 (1992).	
			Fontana et al., "Glioblastoma Cells Release Interleukin 1 and Factors Inhibiting Interleukin 2-Mediated Effects," <i>J. Immunol.</i> 132:1837-1844 (1984).	
			Mapstone et al., "Expression of Platelet-Derived Growth Factors, Transforming Growth Factors, and the <i>ros</i> Gene in a Variety of Primary Human Brain Tumors," <i>Neurosurg.</i> 28:216-222 (1991).	
MB			Marquardt et al., "Complete Amino Acid Sequence of Human Transforming Growth Factor Type Beta 2," <i>J. Biol. Chem.</i> 262:12127-12131 (1987).	
EXAMINER:			DATE 3/6/03	
<small>*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.</small>				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Docket: 4239-60808	App: _____
			Applicant: Shearer et al.	
			Filed: Herewith	Art Unit: _____
OTHER DOCUMENTS				
MB			Morford et al., "Apoptotic Elimination of Peripheral T Lymphocytes in Patients with Primary Intracranial Tumors, <i>J. Neurosurg.</i> 91:935-946 (1999)."	
			Pisetsky, "11. Systemic Lupus Erythematosus. A. Epidemiology, Pathology, and Pathogenesis," in <i>Primer on Rheumatic Diseases</i> , pp. 100-105 (_____.)	
			Schwyzer et al., "Partial Purification and Biochemical Characterization of a T Cell Suppressor Factor Produced by Human Glioblastoma Cells," <i>J. Immunol.</i> 134:1003-1009 (1985).	
MB			Zou et al., "Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) that Alters Monocyte Cytokine Profile and Surface Markers," <i>J. Immunol.</i> 162:4882-4892 (1999).	
EXAMINER: 			DATE 3/6/03	
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.				